Skip to search formSkip to main contentSkip to account menu

AD 5423

Known as: AD-5423 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

blonanserin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
reportFluvoxamine for blonanserin-associated akathisia in patients with schizophrenia : report of five cases
Background: Atypical antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects (EPS) than… 
2005
2005
Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.
Highly Cited
2003
Highly Cited
2003
Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice
The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT2 and a dopamine D2 receptor antagonist… 
1998
1998
AD-5423 Dainippon Pharmaceutical Co Ltd.
  • C. Heading
  • IDrugs : the investigational drugs journal
  • 1998
  • Corpus ID: 25060765
AD-5423, a D(2)/5-HT2 antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other… 
1997
1997
Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection.
Review
1995
Review
1995
[Recent progress in development of psychotropic drugs (2)--antipsychotics].
The discovery of chlorpromazine led to rapid progress in drug therapy for schizophrenia. However, conventional neuroleptics… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)